ClinicalTrials.gg
CompletedNCT01729871VENTURE-AFUpdated Mar 6, 2017Results posted

A Study Exploring Two Treatment Strategies in Patients With Atrial Fibrillation Who Undergo Catheter Ablation Therapy

A Phase 3 interventional study of rivaroxaban and uninterrupted vitamin K antagonist (VKA) in Atrial Fibrillation, sponsored by Janssen Scientific Affairs, LLC. Completed at 44 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-03-06.

Sponsored by Janssen Scientific Affairs, LLC (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
253
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 45 studies testing rivaroxaban in Atrial Fibrillation — 8 open to participants now, 9 under way, none of them phase 3. Rivaroxaban · Atrial Fibrillation.

Enrollment
20th of 45
253 · median 150
Started
2013
with 3 others
Phase 3
16 of 45
none open now
Registered
7th of 45
by date
Lead sponsor
2 of 45
Janssen Scientific Affairs, LLC

Among the 45 studies testing rivaroxaban in Atrial Fibrillation, this one is the 20th largest by enrollment, is one of 4 that started in 2013, is one of 16 in phase 3, and was the 7th registered.

Atrial Fibrillation

4,011 studies on the registry are indexed under Atrial Fibrillation; 960 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

8 of the 45 studies testing rivaroxaban in Atrial Fibrillation are open now, in 4 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About rivaroxaban

Rivaroxaban: first FDA approval 2011 (XARELTO), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 611 Atrial Fibrillation studies recruiting now, 407 (67%) set no upper age limit and 43 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 45 studies testing rivaroxaban in Atrial Fibrillation, or all of them as a file.
02

Study summary

The purpose of this exploratory study is to evaluate the safety of rivaroxaban and uninterrupted vitamin K antagonist (VKA) in adult participants with non-valvular atrial fibrillation (NVAF) who undergo catheter ablation as measured by post-procedure major bleeding events.

Read the detailed description

This is a randomized (participants are assigned to intervention groups by chance), open-label (both physicians and participants know the identity of the assigned treatment), active-controlled, multi-center safety study of rivaroxaban or VKA before and after a catheter ablation procedure. This study requires collaboration with medical institutions that provide access to electrophysiologists who normally perform the catheter ablation procedure. In this study, NVAF is to be defined as the presence of AF in a person who does not have a prosthetic heart valve (annuloplasty with or without prosthetic ring, commissurotomy and/or valvuloplasty are permitted) and who does not have hemodynamically significant mitral valve stenosis. Approximately 250 eligible participants, age 18 years or older, with a history of paroxysmal, persistent, or long standing persistent NVAF who are scheduled to undergo an elective catheter ablation procedure will be randomized in a 1:1 ratio to receive either rivaroxaban 20 mg orally, once-daily, administered preferably with the evening meal or VKA (adjusted to achieve a recommended International Normalized Ratio of 2.0 to 3.0).

The study will consist of a screening period, a pre-procedure period, procedure period and post-procedure period. The screening period will begin up to 2 weeks prior to randomization. Participants will be randomized at the beginning of the pre-procedure period. During this period, participants will be recommended to receive their assigned treatment for at least 4 weeks (maximum of 5 weeks) before the catheter ablation procedure. For participants with the sufficient anticoagulation, documented for the 3 weeks prior to randomization, and for participants with a transesophageal echocardiogram (TEE) or intracardiac echocardiography (ICE), the length of the pre-procedure period may be reduced down to 1-7 days and must include any transition from the previous anticoagulation therapy to randomized study drug.

After the catheter ablation procedure, participants will receive their post-procedure dose of study drug through a minimum of 30 + - 5 days. In addition to scheduled visits and telephone calls the study may also include additional phone calls and visits by the participant to the site when dose adjustment is required for usual care.

03

Conditions studied

  • Atrial Fibrillation

Keywords

  • Atrial Fibrillation
  • Irregular heart beat
  • Catheter Ablation
  • Rivaroxaban
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Be scheduled for a catheter ablation procedure for non-valvular atrial fibrillation (NVAF);
  • Have a documented history of paroxysmal (lasting \<1 week) or persistent (lasting >1 week and \<1 year or requiring pharmacological or electrical cardioversion), or long standing persistent (>=1 year) NVAF;
  • Be suitable for anticoagulant therapy and catheter ablation as per the judgment of the investigator;
  • Women must be before entry or practicing a highly effective method of when heterosexually active;
  • Women of must have a negative serum pregnancy test at screening;
  • Be willing and able to adhere to the prohibitions and restrictions specified in the study protocol;
  • Have a of at least 6 months

Exclusion criteria

Exclusion Criteria:

  • Has a history of a prior stroke, (TIA) or non-convulsive status epilepticus within 6 months of the screening visit;
  • Has a history of a major bleeding or thromboembolic event within the 12 months immediately preceding the catheter ablation procedure;
  • Has had major surgery (requiring general anesthesia), within 6 months before screening or planned surgery during the time the subject is expected to participate in the study;
  • Has NVAF due to electrolyte imbalance, hyperthyroidism, or other reversible or noncardiac cause of NVAF;
  • Has any condition that, in the opinion of the investigator, would make participation not be in the best interest (eg, compromise the well-being) of the participant or that could prevent, limit, or confound the protocol-specified assessments
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
253 participants (actual)

Study arms

  • Experimental
    rivaroxaban

    rivaroxaban 20 mg orally, once-daily, administered preferably with the evening meal

    Drug: rivaroxaban

  • Experimental
    vitamin K antagonist (VKA)

    dose-adjusted vitamin K antagonist (VKA) to achieve a recommended International Normalized Ratio (INR) of 2.0 to 3.0

    Drug: uninterrupted vitamin K antagonist (VKA)

Interventions

  • rivaroxaban 20 mg orally, once-daily, administered preferably with the evening meal

  • Druguninterrupted vitamin K antagonist (VKA)

    dose-adjusted vitamin K antagonist (VKA) to achieve a recommended International Normalized Ratio (INR) of 2.0 to 3.0

06

What researchers measure

Primary outcomes

  1. Number of Participants With Incidence of Post-Procedure Major Bleeding Events

    Post-procedure major bleeding events include Thrombolysis in Myocardial Infarction (TIMI), International Society on Thrombosis and Haemostasis (ISTH) and Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) Severe/life threatening bleeding.

    Time frame: Up to 30 plus or minus (+-) 5 days after the catheter ablation procedure

Secondary outcomes

  1. Number of Participants With Composite Endpoint of Myocardial Infarction (MI), Ischemic Stroke, Non-Central Nervous System (Non-CNS) Systemic Embolism and Vascular Death

    The composite endpoint include Myocardial Infarction (MI), Ischemic Stroke, Non-Central Nervous System (non-CNS) Systemic Embolism and Vascular Death.

    Time frame: Up to 30 plus or minus (+-) 5 days after the catheter ablation procedure

  2. Number of Participants With Myocardial Infarction (MI)

    The MI was defined as clinical symptoms consistent with myocardial ischemia and cardiac biomarker elevation greater than the site's upper limit of normal (ULN) or development of new pathological Q waves in at least 2 contiguous leads on the electrocardiogram (ECG) or autopsy confirmation, OR Creatine kinase-muscle and brain subunit \[or creatine kinase (CK) in the absence of CK-MB\] greater than (\>) 3 or 5 or 10 x ULN for samples obtained within 24 hours of the procedure if the baseline values were normal or at least a 50 percent (%) increase over elevated baseline values that were stable or decreasing or development of new pathological Q waves in at least 2 contiguous leads on the electrocardiogram. Symptoms of cardiac ischemia were not required.

    Time frame: Up to 30 plus or minus (+-) 5 days after the catheter ablation procedure

  3. Number of Participants With Ischemic Stroke

    Stroke was defined as a new, sudden, focal neurological deficit resulting from a presumed cerebrovascular cause that was not reversible within 24 hours and not due to a readily identifiable cause such as a tumor or seizure.

    Time frame: Up to 30 plus or minus (+-) 5 days after the catheter ablation procedure

  4. Number of Participants With Non-Central Nervous System (Non-CNS) Systemic Embolism

    The Non-CNS systemic embolism was defined as abrupt vascular insufficiency associated with clinical or radiological evidence of arterial occlusion in the absence of other likely mechanisms, (example; trauma, atherosclerosis, instrumentation).

    Time frame: Up to 30 plus or minus (+-) 5 days after the catheter ablation procedure

  5. Number of Participants With Vascular Death

    Any death that was not clearly non-vascular. Examples of vascular death included deaths due to bleeding, Myocardial Infarction (MI), stroke, heart failure and arrhythmias.

    Time frame: Up to 30 plus or minus (+-) 5 days after the catheter ablation procedure

07

Results

Posted Nov 10, 2015

Participant flow

Participants were randomized at 37 sites in 5 countries.

Participant flow — Overall Study
MilestoneRivaroxabanVitamin K Antagonist
Started124124
Completed112101
Not completed1223
Withdrew: Adverse event77
Withdrew: Death01
Withdrew: Lack of efficacy01
Withdrew: Physician decision02
Withdrew: Protocol violation10
Withdrew: Withdrawal by subject03
Withdrew: Other49

Outcome measures

PrimaryNumber of Participants With Incidence of Post-Procedure Major Bleeding Events

Post-procedure major bleeding events include Thrombolysis in Myocardial Infarction (TIMI), International Society on Thrombosis and Haemostasis (ISTH) and Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) Severe/life threatening bleeding.

Time frame:
Up to 30 plus or minus (+-) 5 days after the catheter ablation procedure
Reported as:
Number · Participants
Number of Participants With Incidence of Post-Procedure Major Bleeding Events
ParticipantsRivaroxabanVitamin K Antagonist
TIMI Major Bleeding00
ISTH Major Bleeding01
GUSTO Severe/Life Threatening Bleeding00
SecondaryNumber of Participants With Composite Endpoint of Myocardial Infarction (MI), Ischemic Stroke, Non-Central Nervous System (Non-CNS) Systemic Embolism and Vascular Death

The composite endpoint include Myocardial Infarction (MI), Ischemic Stroke, Non-Central Nervous System (non-CNS) Systemic Embolism and Vascular Death.

Time frame:
Up to 30 plus or minus (+-) 5 days after the catheter ablation procedure
Reported as:
Number · Participants
Number of Participants With Composite Endpoint of Myocardial Infarction (MI), Ischemic Stroke, Non-Central Nervous System (Non-CNS) Systemic Embolism and Vascular Death
ParticipantsRivaroxabanVitamin K Antagonist
Number of Participants With Composite Endpoint of Myocardial Infarction (MI), Ischemic Stroke, Non-Central Nervous System (Non-CNS) Systemic Embolism and Vascular Death02
SecondaryNumber of Participants With Myocardial Infarction (MI)

The MI was defined as clinical symptoms consistent with myocardial ischemia and cardiac biomarker elevation greater than the site's upper limit of normal (ULN) or development of new pathological Q waves in at least 2 contiguous leads on the electrocardiogram (ECG) or autopsy confirmation, OR Creatine kinase-muscle and brain subunit \[or creatine kinase (CK) in the absence of CK-MB\] greater than (\>) 3 or 5 or 10 x ULN for samples obtained within 24 hours of the procedure if the baseline values were normal or at least a 50 percent (%) increase over elevated baseline values that were stable or decreasing or development of new pathological Q waves in at least 2 contiguous leads on the electrocardiogram. Symptoms of cardiac ischemia were not required.

Time frame:
Up to 30 plus or minus (+-) 5 days after the catheter ablation procedure
Reported as:
Number · Participants
Number of Participants With Myocardial Infarction (MI)
ParticipantsRivaroxabanVitamin K Antagonist
Number of Participants With Myocardial Infarction (MI)00
SecondaryNumber of Participants With Ischemic Stroke

Stroke was defined as a new, sudden, focal neurological deficit resulting from a presumed cerebrovascular cause that was not reversible within 24 hours and not due to a readily identifiable cause such as a tumor or seizure.

Time frame:
Up to 30 plus or minus (+-) 5 days after the catheter ablation procedure
Reported as:
Number · Participants
Number of Participants With Ischemic Stroke
ParticipantsRivaroxabanVitamin K Antagonist
Number of Participants With Ischemic Stroke01
SecondaryNumber of Participants With Non-Central Nervous System (Non-CNS) Systemic Embolism

The Non-CNS systemic embolism was defined as abrupt vascular insufficiency associated with clinical or radiological evidence of arterial occlusion in the absence of other likely mechanisms, (example; trauma, atherosclerosis, instrumentation).

Time frame:
Up to 30 plus or minus (+-) 5 days after the catheter ablation procedure
Reported as:
Number · Participants
Number of Participants With Non-Central Nervous System (Non-CNS) Systemic Embolism
ParticipantsRivaroxabanVitamin K Antagonist
Number of Participants With Non-Central Nervous System (Non-CNS) Systemic Embolism00
SecondaryNumber of Participants With Vascular Death

Any death that was not clearly non-vascular. Examples of vascular death included deaths due to bleeding, Myocardial Infarction (MI), stroke, heart failure and arrhythmias.

Time frame:
Up to 30 plus or minus (+-) 5 days after the catheter ablation procedure
Reported as:
Number · Participants
Number of Participants With Vascular Death
ParticipantsRivaroxabanVitamin K Antagonist
Number of Participants With Vascular Death01

Adverse events

Collected over Screening up to Week 8-10. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Rivaroxaban—17/123 (13.8%)26/123 (21.1%)
Vitamin K Antagonist—20/121 (16.5%)20/121 (16.5%)
Most frequent serious events
Showing 10 of 33
Most frequent serious events
EventRivaroxabanVitamin K Antagonist
Atrial fibrillationCardiac disorders3/1235/121
Vascular pseudoaneurysmInjury, poisoning and procedural complications2/1232/121
BradycardiaCardiac disorders2/1230/121
PyrexiaGeneral disorders2/1230/121
AnaemiaBlood and lymphatic system disorders0/1231/121
Acute myocardial infarctionCardiac disorders0/1231/121
Atrial tachycardiaCardiac disorders0/1231/121
Cardiac failureCardiac disorders0/1231/121
PericarditisCardiac disorders1/1231/121
Sinus arrestCardiac disorders0/1231/121
Most frequent other events
Most frequent other events
EventRivaroxabanVitamin K Antagonist
Atrial fibrillationCardiac disorders10/12310/121
HaematomaVascular disorders9/1239/121
FatigueGeneral disorders8/1232/121

Baseline characteristics

Age, Continuous
Age, Continuous(years)RivaroxabanVitamin K AntagonistTotal
Mean58.6 ± 9.8660.5 ± 10.5159.5 ± 10.21
Sex: Female, Male
Sex: Female, Male(Participants)RivaroxabanVitamin K AntagonistTotal
Female383472
Male8690176
Region of Enrollment
Region of Enrollment(participants)RivaroxabanVitamin K AntagonistTotal
Belgium242448
France191938
Germany181937
Great Britain242448
United States of America393877
Race
Race(participants)RivaroxabanVitamin K AntagonistTotal
ASIAN527
BLACK336
N/A437
WHITE112116228
Ethnicity
Ethnicity(participants)RivaroxabanVitamin K AntagonistTotal
HISPANIC/LATINO044
N/A342660
NOT HISPANIC/LATINO9094184
Body-Mass Index
Body-Mass Index(kg/m^2)RivaroxabanVitamin K AntagonistTotal
Mean29.8 ± 5.7428.9 ± 5.4929.4 ± 5.62
Diastolic Blood Pressure
Diastolic Blood Pressure(mmHg)RivaroxabanVitamin K AntagonistTotal
Mean81 ± 9.8579.4 ± 10.7880.2 ± 10.34
Systolic Blood Pressure
Systolic Blood Pressure(mmHg)RivaroxabanVitamin K AntagonistTotal
Mean133.3 ± 15.6131.2 ± 17.68132.2 ± 16.67
08

Study locations

44 sites
  • Beverly Hills, California, United States
  • Los Angeles, California, United States
  • Sacramento, California, United States
  • San Francisco, California, United States
  • Jacksonville, Florida, United States
  • Maywood, Illinois, United States
  • Kansas City, Kansas, United States
  • Boston, Massachusetts, United States
  • St Louis Park, Minnesota, United States
  • Ridgewood, New Jersey, United States
  • Flushing, New York, United States
  • Durham, North Carolina, United States
  • Columbus, Ohio, United States
  • Portland, Oregon, United States
  • Erie, Pennsylvania, United States
  • Hershey, Pennsylvania, United States
  • Philadelphia, Pennsylvania, United States
  • Nashville, Tennessee, United States
  • Austin, Texas, United States
  • Dallas, Texas, United States
  • Tyler, Texas, United States
  • Charlottesville, Virginia, United States
  • Seattle, Washington, United States
  • Tacoma, Washington, United States
  • Aalst, Belgium
  • Antwerpen, Belgium
  • Brugge, Belgium
  • Genk, Belgium
  • Hasselt, Belgium
  • Brest Cedex 2, France
  • Montpellier, France
  • Pessac Cedex, France
  • Toulouse Cedex 9 N/A, France
  • Vandoeuvre Les Nancy, France
  • Bad Krozingen, Germany
  • Bad Nauheim, Germany
  • Berlin, Germany
  • Dresden, Germany
  • Jena, Germany
  • Mönchengladbach, Germany
  • Neuwied, Germany
  • Bournemouth, United Kingdom
  • Cottingham, United Kingdom
  • London, United Kingdom
09

References and documents

Publications

  • Cappato R, Marchlinski FE, Hohnloser SH, Naccarelli GV, Xiang J, Wilber DJ, Ma CS, Hess S, Wells DS, Juang G, Vijgen J, Hugl BJ, Balasubramaniam R, De Chillou C, Davies DW, Fields LE, Natale A; VENTURE-AF Investigators. Uninterrupted rivaroxaban vs. uninterrupted vitamin K antagonists for catheter ablation in non-valvular atrial fibrillation. Eur Heart J. 2015 Jul 21;36(28):1805-11. doi: 10.1093/eurheartj/ehv177. Epub 2015 May 14. PubMed 25975659 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2013, a primary completion of Oct 2014 and a completion of Oct 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2015, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 23, 2012
First posted
Nov 20, 2012
Start
Feb 2013
Primary completionActual
Oct 2014
CompletionActual
Oct 2014
Results first posted
Nov 10, 2015
Last update
Mar 6, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 6, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01729871
Collaborators
Bayer
Responsible party
Sponsor
First posted
Nov 20, 2012
Start date
Feb 2013
Primary completion
Oct 2014
Completion
Oct 2014
Results posted
Nov 10, 2015
Last update
Mar 6, 2017

Study contacts

Janssen Scientific Affairs, LLC Clinical Trial
study director · Janssen Scientific Affairs, LLC

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rivaroxaban

Start the discussion